Compare Ralph Lauren Corp (RL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ralph Lauren Corp vs Recursion Pharmaceuticals Inc — how do they compare? Ralph Lauren Corp trades at $340.2 (market cap $20.69B), while Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B). The key difference: Ralph Lauren Corp is far larger — about 11.1× Recursion Pharmaceuticals Inc's market cap, and Ralph Lauren Corp pays a 1.15% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RL | RXRX | |
|---|---|---|
Market Cap | $20.69B | $1.86B |
Sector | Consumer Cyclical | Health |
52-Week High | $414.25 | $6.79 |
52-Week Low | $302.89 | $2.84 |
Enterprise Value | $21.75B | $1.38B |
Dividend Yield | 1.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ralph Lauren (RL) trades at $347.23, down 1.13% on the day, with the stock showing bearish technical signals despite strong fundamentals. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.59 surpassing the $4.32 estimate. Revenue growth has accelerated from $6.2B in 2022 to $7.1B in 2025, while net income margins improved to 10.49%. Recent corporate developments include a new cancer center partnership in South Korea and ongoing AI investments to enhance customer experience.
The investment outlook remains positive with 66% analyst buy ratings and a $456.50 consensus price target representing 31% upside potential. However, the stock faces near-term technical pressure with bearish moving averages and faces execution risks in maintaining luxury brand positioning amid economic uncertainty. Strong profitability metrics including 37.54% ROE and improving cash flow generation support the long-term growth thesis.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
